| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.6 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.6 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | AGK-2 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |